Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jose Camacho

Clinical Genetics (M.D.) San Francisco, CA Medical Doctor

NPI 1255548327 CMS profile 1253164

1825 4Th St Fl 6, San Francisco, CA 94143

Open in the dashboard

General payments

$125,752

153 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jose Camacho of San Francisco, CA is reported in the CMS Open Payments database as having received $125,752 across 153 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Clinical Genetics (M.D.) profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $134 2
2024 General $67,044 47
2023 General $32,897 39
2022 General $5,276 16
2021 General $9,265 11
2020 General $3,187 13
2019 General $7,948 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jose Camacho
  • Clinical Genetics (M.D.) median
  • Middle half of Clinical Genetics (M.D.)
  • National median

In program year 2025, general payments to Jose Camacho were reported at $134. Among 315 Clinical Genetics (M.D.) profiles paid that year, the median was $255 and the middle half received between $85 and $3,583.

Show as a table
Year Jose Camacho Clinical Genetics (M.D.) median Middle half National median
2019 $7,948 $130 $24–$2,691 $163
2020 $3,187 $126 $30–$3,700 $114
2021 $9,265 $185 $30–$3,777 $132
2022 $5,276 $136 $44–$2,749 $149
2023 $32,897 $196 $55–$5,220 $160
2024 $67,044 $165 $46–$3,171 $164
2025 $134 $255 $85–$3,583 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $120,047 111 payments
  2. Amgen Inc. $3,073 4 payments
  3. Horizon Therapeutics plc $2,361 5 payments
  4. Retrophin, Inc. $90 28 payments
  5. Orchard Therapeutics North America $61 1 payment
  6. BioMarin Pharmaceutical Inc. $56 1 payment
  7. Shire North American Group Inc $34 2 payments
  8. Ultragenyx Pharmaceutical Inc. $30 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $97,724 35 payments
  2. Travel and Lodging $19,915 39 payments
  3. Food and Beverage $2,944 48 payments
  4. Consulting Fee $2,800 1 payment
  5. Honoraria $2,250 1 payment
  6. Education $120 29 payments
Products named General payments · program years 2019–2025
  1. FABRAZYME Genetic Disease $57,493 42 payments
  2. XENPOZYME $43,937 38 payments
  3. FABRAZYME Rare Disease Genetics $6,520 7 payments
  4. RAVICTI Metabolic Disorders/Rare Disease $3,073 4 payments
  5. LUMIZYME $2,499 2 payments
  6. PROCYSBI $2,250 1 payment
  7. NEXVIAZYME $1,792 1 payment
  8. NO PRODUCT DISCUSSED $1,288 8 payments
  9. RAVICTI Ravicti $111 4 payments
  10. LENMELDY $61 1 payment
  11. Other $210 32 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

153 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Genetics (M.D.) in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record